Development and Validation of a Novel High Throughput Label-Free Screening System for Antibody Discovery

Waltham, MA and Woburn, MA – X-BODY Biosciences and SRU Biosystems today announced a major collaborative advance in the application of the SRU BIND® label-free protein detection platform for high-throughput label-free screening of high affinity antibodies. The two companies have developed and validated a novel BIND® Biosensor design for use with the commercially available SRU BIND® Reader that results in a >200-fold increase in sensitivity over SRU’s previous sensor. The novel biosensor allows for measurement of sub-nanomolar affinity interactions in an automated microplate format.

Commenting on the recent development, Dr. Yan Chen, X-BODY’s Vice President of Antibody Research, said, “For years, the therapeutic antibody community has sought a label-free, high throughput screening platform to accelerate the drug discovery process. This improved BIND® protein detection system offers unprecedented throughput and sensitivity for antibody screening.”

The improved SRU BIND® system allows for high affinity measurements in 384 or 1536 well microplate formats for diagnostic, manufacturing QC and drug discovery applications. X-BODY Biosciences has developed a novel platform for rapidly screening fully human antibody libraries that incorporates the improved SRU BIND® Biosensor. X-BODY has validated the use of this new and improved SRU BIND® system for drug discovery by employing the technology to rapidly identify and characterize therapeutic candidates.

About X-BODY Biosciences

X-BODY Biosciences was founded in 2008 by Richard Wagner, Gordon Binder, and Brant Binder. Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GSK in 2007. Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of the American Enterprise Institute, the Massachusetts Institute of Technology and the California Institute of Technology. Mr. Brant Binder is co-founder, COO and CFO of SRU Biosystems. X-BODY’s platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY’s versatile selection system employs NextGeneration sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. The platform is available for collaboration and is scalable to support global discovery efforts. X-BODY has employed the platform internally to identify high-affinity therapeutic candidates that target metastasis (invasion and spreading) of cancer stem cells

Further information regarding X-BODY Biosciences can be obtained at

WEB: www.x-bodybiosciences.com

EMAIL: BD@x-bodybiosciences.com

About SRU Biosystems

SRU Biosystems, Inc. is a life science company developing novel technologies for rapidly analyzing the interactions of large genomic, protein, peptide, antibody or small molecule compound libraries against a wide range of biochemical and cellular targets. SRU is incorporating its BIND® technology into microtiter plates, microarray slides and other industry standard formats to create sensitive and high throughput tools that can be used to answer important biological questions for biomedical research, pharmaceutical drug discovery and diagnostics.

Further information regarding SRU Biosystems can be obtained at:

WEB: www.srubiosystems.com

EMAIL: info@srubiosystems.com